Vertex extends research program with Merck

New York, June 26 - Vertex Pharmaceuticals Inc. said it extended its research collaboration agreement with Merck & Co., Inc.

The expiration is now Sept. 21, 2006, according to an 8-K filing with the Securities and Exchange Commission.

The two companies signed the research collaboration, license and commercialization agreement on June 21, 2004.

Vertex is a Cambridge, Mass., biotechnology company focused on the discovery and development of small molecule drugs for serious diseases.

Merck, based in Whitehouse Station, N.J., is a research-driven pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.